ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

ANN ARBOR, Mich.–(BUSINESS WIRE)—- $NDRA #MASLD–ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the third quarter ended September 30, 2026, and provided a business update. Business Update During the third quarter of 2026, ENDRA continued to manage its operating costs while continue to develop its third-generation ultrasound product. At th

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.